Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2022

CY6463 administration in healthy participants was associated with improvements in Alzheimer’s diseaserelevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI.

Martin Kindermans 1, Hichem Chakroun 1, Jennifer Chickering 2, Chad Glasser 2, Pablo Iriso 1, Frederic Parmentier 1, Todd Milne 2, Phebe Wilson 2, Mohammad Afshar 1 1Tersan Pharmaceuticals Ltd – Paris (France), 2Cyclerion – Cambridge (United Kingdom)